GT Biopharma (GTBP) Technology Killing Lymphoma and Leukemia Cells
GT Biopharma Inc (NASDAQ:GTBP) uplisted to NASDAQ on Feb 15th, 2021, with a $50 million valuation. Now, the stock is trading at over $500 million just half a year later. So what has caused the huge excitement in the sometimes speculative biotech sector? GT Biopharma is doing what no one else can do and has developed the technology to kill cancer cells, such as lymphoma, leukemia and multiple solid tumours, with no side effects.
GT Biopharma is not your average preclinical biotech company hoping its drug will work. The company has real clinical FDA clinical trial data proving its technology is a serial killer of cancer cells. Perhaps just as importantly, this technology delivers no side effects and toxicity to the human body. The results are life-changing. GT Biopharma is seeing benefits of up to 70% elimination of leukemia cells inside patient’s bone marrow (where the cancer comes from).
“Everything happens in the bone marrow, that’s where leukemia comes from. We’re eliminating those cells to a large degree. That has surprised the market. That’s why we are up 500%. But, the good news for your audience is we are still the lowest market cap in that field which goes from $1 billion to $8.5 billion while the other players have to do all that stuff outside of your body. So, that’s the opportunity. Most importantly for me is to be able to deliver a cancer therapeutic that is so easily tolerated. Patients have had the crap kicked out of them for years fighting their fight with cancer and we come along with a very easily tolerated drug. Even they are amazed.” – GT Biopharma CEO Anthony Cataldo
The therapy GT Biopharma is focusing on is its proprietary NK cell engager (TriKE™) technology. TriKE™ therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells. This technology is patented and is far cheaper to develop than drugs trying to perform the same function. Other biotech players spend $300,000 to $1 million per patient running clinical trials, GT Biopharma has spent only $30,000. This cost advantage speaks volumes to the economics of the new therapy.
The company has the cash on hand to operate for a few years with no debt and, even after its 500% share price increase, is still trading at a 50% to a 95% discount from other companies in the same field.
Watch the full interview to learn about GT Biopharma’s new cancer-killing technology, its latest clinical trials, and the opportunity in its share price value.
01:12 – GT Biopharma overview
02:50 – Nasdaq up-listing
03:27 – Manufacturing/trials costs
04:00 – Patient experience
04:17 – NK cells
06:03 – Clinical FDA trial data
07:00 – No drug side effects
07:19 – Trial patient outcomes
08:02 – Company valuation
09:17 – Capital structure
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.